Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

Cell & Gene Therapy Insights 2023; 9(5), 709–717

DOI: 10.18609/cgti.2023.089

Published: 27 June
Adrian Bot

The application of lipid nanoparticles (LNPs) as a non-viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.